Virax Holdings Limited operates in the Pharmaceutical preparations sector. Virax Holdings Limited (Virax) is a biopharmaceutical company. The Company is engaged in the discovery and development of immunotherapeutic products for the treatment of chronic infectious diseases and cancer. It is developing immunotherapeutics based upon its Co-X-Gene and fowlpox virus (FPV) delivery technologies. The Company's activities include construction of vectors and biologic components and manufacture of biologic drugs for clinical trial purposes; preparation for and conduct of clinical trials; business development associated with promotion of Virax's proprietary technologies; business development associated with developing collaborative, partnership relationships and corporate transactions, and capital raising to provide funds to undertake further activities. Its lead product is VIR201. During the fiscal year ended June 30, 2010, it completed Phase II testing of its human papilloma virus (HPV) based vaccine (TG4001) and Phase IIb testing of its lung cancer vaccine (TG4010).